Synutra International Inc. (SYUT) Drops 6.94% on February 11

Equities Staff |

Synutra International Inc. (SYUT) was one of the Russell 2000's biggest losers for Thursday February 11 as the stock slid 6.94% to $4.69, a loss of $-0.35 per share. Starting at an opening price of $4.93 a share, the stock traded between $4.65 and $4.96 over the course of the trading day. Volume was 93,641 shares over 532 trades, against an average daily volume of 62,980 shares and a total float of 56.84 million.

The losses send Synutra International Inc. down to a market cap of $266.56 million. In the last year, Synutra International Inc. has traded between $8.15 and $3.62, and its 50-day SMA is currently $4.77 and 200-day SMA is $5.69.

The stock has a P/E Ratio of 6.5.

Synutra International Inc is engaged in production, distribution & sales of dairy based nutritional products under Shengyuan or Synutra line of brands in China. Its other nutritional product includes prepared foods, nutritional ingredients & supplements.

Synutra International Inc. is based out of Rockville, MD and has some 2,700 employees. Its CEO is Liang Zhang.

For a complete fundamental analysis analysis of Synutra International Inc., check out’s Stock Valuation Analysis report for SYUT. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…


A peer-to-Peer authentic photo marketplace disrupting the $10B commercial photography industry.